Vertebral Compression Fractures: Causes, Symptoms, and Treatment Options

What Is a Vertebral Compression Fracture?

A vertebral compression fracture is a collapse of one or more vertebral bodies in the spine, typically losing 20% or more of their normal height. The vertebral body, the block-shaped anterior portion of each vertebra, bears most of the axial load during standing and movement. When bone strength falls below the mechanical stress applied to it, the vertebra buckles.

VCFs represent the most common osteoporotic fracture type. Data from the National Osteoporosis Foundation estimate 1.5 million osteoporotic fractures annually in the United States, with vertebral fractures accounting for nearly half that total [1]. The thoracolumbar junction (T11 through L2) is the most vulnerable segment because it sits at the transition between the relatively rigid thoracic spine and the more mobile lumbar spine.

Two-thirds of VCFs are clinically silent. Patients may not recall a specific injury. The fracture is discovered incidentally on a chest X-ray or CT scan ordered for another reason. When symptoms do appear, they typically include sudden-onset midline back pain worsened by standing or bending, point tenderness over the affected spinous process, and difficulty with daily activities like dressing or reaching overhead [2]. Progressive fractures lead to height loss and thoracic kyphosis, the rounded "dowager's hump" posture that reduces lung capacity and compresses abdominal organs.

Why Osteoporosis Is the Primary Driver

Osteoporosis causes 70% of VCFs in adults over age 50, and the mechanism is straightforward. Normal bone remodeling depends on a balance between osteoclast-mediated resorption and osteoblast-mediated formation. When resorption outpaces formation, trabecular microarchitecture deteriorates, cortical thickness decreases, and fracture threshold drops.

Postmenopausal bone loss is the single largest contributor. Estrogen normally suppresses osteoclast activity by modulating RANKL signaling. Within the first 5 to 7 years after menopause, women can lose up to 20% of their total bone density [3]. The 2020 Endocrine Society Clinical Practice Guideline noted that "postmenopausal osteoporosis remains underdiagnosed and undertreated, with fewer than 25% of women who sustain a fragility fracture receiving appropriate pharmacotherapy within 12 months" [4].

Male osteoporosis, though less discussed, accounts for roughly 25% of all osteoporotic VCFs. In men, age-related testosterone decline contributes to bone loss through reduced aromatization to estradiol, which is the primary hormonal mediator of bone resorption even in males. The Osteoporotic Fractures in Men (MrOS) study followed 5,994 men aged 65 and older and found that those with baseline vertebral fractures had a 3.2-fold increased risk of subsequent clinical fractures over 4.7 years of follow-up [5].

Other causes of VCFs include metastatic cancer (especially breast, lung, prostate, and multiple myeloma), long-term glucocorticoid use exceeding 7.5 mg prednisone-equivalent daily, and high-energy trauma in younger patients.

Diagnosing Vertebral Compression Fractures

The diagnostic workup starts simple. A lateral thoracolumbar X-ray reveals the fracture in most cases, showing anterior wedging, biconcavity, or uniform collapse of the vertebral body.

The Genant semiquantitative grading system classifies VCFs by height reduction: Grade 1 is 20% to 25% loss, Grade 2 is 25% to 40%, and Grade 3 exceeds 40% [6]. This standardized approach matters because higher-grade fractures predict worse outcomes and greater refracture risk.

MRI with STIR (short tau inversion recovery) sequences is the gold standard for determining fracture acuity. Bone marrow edema on STIR imaging indicates a fracture less than 2 to 3 months old, which guides treatment decisions, particularly eligibility for cement augmentation procedures. MRI also distinguishes osteoporotic fractures from pathologic fractures caused by tumor infiltration. When MRI is contraindicated, a bone scan (technetium-99m scintigraphy) or CT scan with contrast serves as an alternative.

Every patient with a new VCF needs a DEXA scan to quantify bone mineral density [7]. The World Health Organization defines osteoporosis as a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip. Osteopenia falls between -1.0 and -2.5. A FRAX score (Fracture Risk Assessment Tool) should be calculated simultaneously to estimate 10-year major osteoporotic fracture probability.

Laboratory evaluation includes serum calcium, phosphorus, 25-hydroxyvitamin D, PTH, CBC, and a metabolic panel. In men and premenopausal women, consider checking testosterone, TSH, and serum protein electrophoresis to rule out secondary causes.

Conservative Treatment: The First-Line Approach

Most VCFs heal with nonoperative management over 6 to 12 weeks. The goal is pain control, early mobilization, and prevention of deconditioning.

Pain management follows a stepwise protocol. Acetaminophen (up to 3 g daily in patients without liver disease) serves as the baseline. NSAIDs provide additional relief but carry gastrointestinal and renal risks in older adults. Short courses of low-dose opioids (5 to 10 mg oxycodone every 6 hours for 1 to 2 weeks) may be necessary for severe pain, though the American College of Physicians guidelines recommend limiting opioid duration [8]. Calcitonin nasal spray (200 IU daily) has shown modest analgesic benefit specific to acute VCF pain in a 2012 Cochrane review (N=589 across 6 trials), reducing pain scores by approximately 2 points on a 10-point VAS within 4 weeks [9].

Bracing with a thoracolumbar orthosis (TLSO) or Jewett-type hyperextension brace provides external support, limits flexion, and reduces pain during the acute phase. There is no high-quality evidence that bracing accelerates fracture healing, but it often permits earlier return to upright activity. Prolonged brace wear beyond 8 to 12 weeks is discouraged because it can cause truncal muscle atrophy.

Bed rest should be strictly limited. Even 48 hours of immobilization in elderly patients accelerates muscle wasting, increases thromboembolic risk, and worsens bone loss. Physical therapy should begin as soon as pain permits, focusing on extension-based exercises, postural training, and fall-prevention strategies.

Vertebroplasty and Kyphoplasty: When Surgery Is Considered

Cement augmentation procedures are indicated when pain persists beyond 4 to 6 weeks of conservative care, when progressive vertebral collapse threatens spinal alignment, or when functional decline is severe.

Vertebroplasty involves percutaneous injection of polymethylmethacrylate (PMMA) bone cement into the fractured vertebral body under fluoroscopic guidance. The procedure takes 30 to 60 minutes per level and is typically performed under conscious sedation. The evidence is mixed. Two sham-controlled trials, INVEST (N=131) and the Australian trial by Buchbinder et al. (N=78), found no significant difference in pain or disability between vertebroplasty and sham at 1 and 6 months [10, 11]. These results challenged earlier open-label studies showing benefit.

Balloon kyphoplasty uses an inflatable bone tamp to create a cavity within the vertebral body before cement injection, which partially restores vertebral height and may reduce kyphotic deformity. The FREE trial (Fracture Reduction Evaluation), a multicenter RCT of 300 patients, compared balloon kyphoplasty to nonsurgical management and found that kyphoplasty patients had significantly greater improvements in SF-36 physical component scores (8.4 vs. 0.7 points, P<0.001) and EQ-5D quality-of-life scores at 1 month, with benefits sustained at 12 months [12]. Pain relief was rapid: 92% of kyphoplasty patients reported clinically meaningful pain reduction by day 7.

Dr. Isador Lieberman, who pioneered early kyphoplasty techniques at the Cleveland Clinic, has stated: "The key is patient selection. Cement augmentation works best in patients with acute fractures showing marrow edema on MRI, significant pain limiting function, and failure of at least three to four weeks of conservative therapy."

Complications of cement procedures include cement leakage (occurring in 5% to 10% of kyphoplasty cases and up to 30% of vertebroplasty cases), adjacent-level fractures, pulmonary cement embolism (rare but reported), and infection. The VERTOS II trial (N=202), which compared vertebroplasty to conservative treatment (not sham), did find greater pain relief and functional improvement with vertebroplasty at 1 month and 12 months [13].

The Cascade Effect: Why One Fracture Predicts the Next

A single vertebral compression fracture increases the risk of subsequent vertebral fracture by approximately 5-fold within the first year [14]. This "fracture cascade" is driven by biomechanical and biological factors that compound each other.

Biomechanically, a collapsed vertebra shifts the spine's center of gravity anteriorly. This increases flexion forces on adjacent vertebral bodies by 20% to 30%, pushing already-weakened bone past its failure threshold. The result is often a domino pattern of sequential fractures moving cranially through the thoracic spine. Biologically, the inflammatory response at the fracture site activates local osteoclasts, accelerating bone resorption in the surrounding vertebrae.

The clinical significance is severe. Data from the Study of Osteoporotic Fractures demonstrated that women with two or more vertebral fractures had a 23% to 34% increase in age-adjusted mortality compared to women without fractures, primarily driven by respiratory complications from progressive kyphosis [15]. Loss of thoracic height compresses lung volume by up to 9% per fractured vertebra, contributing to restrictive lung disease and pneumonia risk.

This cascade makes aggressive secondary fracture prevention non-negotiable after any VCF diagnosis.

Pharmacologic Prevention and Treatment of the Underlying Disease

Treating the fracture without treating the osteoporosis is a clinical failure. Every patient with a VCF needs bone-protective pharmacotherapy unless contraindicated.

Bisphosphonates remain the first-line agents for most patients. Alendronate (70 mg weekly) reduced vertebral fracture risk by 47% over 3 years in the FIT trial (N=2,027) [16]. Zoledronic acid (5 mg IV annually) is preferred for patients with poor oral tolerance or adherence concerns. The HORIZON Recurrent Fracture Trial (N=2,127) showed that zoledronic acid given within 90 days of hip fracture repair reduced clinical fracture rates by 35% and all-cause mortality by 28% over a median follow-up of 1.9 years [17].

Denosumab (60 mg subcutaneously every 6 months) is a RANKL inhibitor that reduced new vertebral fractures by 68% in the FREEDOM trial (N=7,868) over 36 months [18]. It carries a unique concern: discontinuation causes rapid rebound bone loss and a cluster of vertebral fractures within 7 to 12 months. The 2020 AACE guidelines state that "denosumab should not be discontinued without a transition plan, ideally involving a bisphosphonate bridge" [19].

Anabolic agents are reserved for severe osteoporosis or patients who fracture despite antiresorptive therapy. Teriparatide (Forteo, 20 mcg subcutaneously daily) stimulates osteoblast activity and reduced vertebral fracture risk by 65% over 21 months in its key trial (N=1,637) [20]. Romosozumab (Evenity, 210 mg subcutaneously monthly for 12 months) is a sclerostin inhibitor with dual anabolic and antiresorptive action. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone over 24 months [21]. Romosozumab carries a boxed warning for cardiovascular risk and is contraindicated in patients with recent MI or stroke.

Calcium, Vitamin D, and Lifestyle Interventions

Pharmacotherapy works best on a foundation of adequate calcium and vitamin D. The National Osteoporosis Foundation recommends 1 to 200 mg of daily calcium (preferably from dietary sources) and 800 to 1 to 000 IU of vitamin D3 for adults over 50 [22]. Serum 25-hydroxyvitamin D should be maintained above 30 ng/mL. Patients with documented deficiency (<20 ng/mL) may need loading doses of 50 to 000 IU weekly for 6 to 8 weeks before transitioning to maintenance dosing.

Weight-bearing exercise (walking, stair climbing) and resistance training stimulate osteoblast activity and reduce fracture risk independently of pharmacotherapy. A meta-analysis of 43 RCTs found that combined exercise programs reduced vertebral fracture incidence by 56% (RR 0.44 to 95% CI 0.27 to 0.72) [23]. Tai chi programs have shown a 50% reduction in fall rates among community-dwelling older adults.

Avoid flexion-based exercises (sit-ups, toe touches, heavy forward bending) in patients with existing VCFs, as these increase anterior compressive forces on already-compromised vertebrae. Extension and isometric trunk strengthening are safer and more effective for this population.

Smoking cessation and alcohol limitation (no more than two drinks daily) both have direct bone-protective effects. Smoking accelerates estradiol metabolism and impairs osteoblast function, while excessive alcohol suppresses bone formation markers.

Special Populations: Postmenopausal Women and Men With Hypogonadism

Postmenopausal women face the highest absolute risk of VCFs. The DEXA screening recommendation from the U.S. Preventive Services Task Force applies to all women aged 65 and older, and to younger postmenopausal women with clinical risk factors (low body weight, prior fracture, parental hip fracture, smoking, glucocorticoid use) [24].

Hormone replacement therapy (HRT) with estrogen reduces vertebral fracture risk by 34%, as demonstrated in the Women's Health Initiative (N=16 to 608 in the estrogen-progestin arm) [25]. Current practice favors HRT initiation within 10 years of menopause for women with vasomotor symptoms who also have osteoporosis risk, rather than using HRT solely for bone protection.

Men with hypogonadal osteoporosis benefit from testosterone replacement therapy (TRT), which increases lumbar spine BMD by 3% to 8% over 12 to 24 months in multiple studies. The Endocrine Society guidelines recommend evaluating men with VCFs for secondary causes including hypogonadism, and initiating TRT when total testosterone is consistently below 300 ng/dL alongside clinical symptoms [26]. TRT should be combined with an antiresorptive or anabolic agent in men with T-scores below -2.5 or prevalent fractures.

Patients on chronic glucocorticoids (prednisone ≥2.5 mg daily for 3 months or longer) should receive prophylactic bisphosphonate therapy per ACR 2022 guidelines, regardless of DEXA results, given the rapid and profound effect of glucocorticoids on trabecular bone [27].